CTOs on the Move

Epimed International

www.epimedpain.com

 
Epimed International is a Johnstown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Metamason

Metamason is dedicated to improving healthcare through technological innovation. Our health-focused software platform uses 3D scans of the body to create individually customized, 3D-printed products engineered for flawless fit.

Alliance Medical Services

Alliance Medical Services is a Holland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Koya

Koya Medical is a transformative healthcare venture with a mission to treat cancer-related chronic lymphedema and venous diseases through innovative patient-centric platforms.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.

Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including arterial calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.